The federal government is preparing to outlaw many full-spectrum hemp products while withholding basic information businesses need to understand the new law. If you care about your access to CBD and other non-intoxicating cannabinoids, please sign our Action Alert now!
Listen to the audio version of this article:
THE TOPLINE
- FDA missed its February 10 deadline to clarify which cannabinoids count toward the new 0.4-milligram-per-container limit and what constitutes a “container,” leaving hemp businesses unable to prepare for the December 2026 restrictions.
- The new definition threatens many non-intoxicating, full-spectrum CBD products—not just synthetic intoxicants.
- Congress should enact the Hemp Planting Predictability Act to delay implementation and the Cannabinoid Safety and Regulation Act to establish risk-based safety standards while preserving access to responsibly made hemp products.
The Food and Drug Administration (FDA) was supposed to publish critical cannabinoid lists and clarify key packaging rules by February 10. More than six months later, consumers, farmers, and responsible hemp businesses are still waiting.
FDA Misses a Mandatory Deadline
Congress created this confusion when it included sweeping hemp restrictions in the fiscal year 2026 appropriations law signed in November 2025.
The law gave FDA 90 days to publish three lists: cannabinoids that can occur naturally in cannabis, naturally occurring tetrahydrocannabinol (THC)-class cannabinoids, and other cannabinoids known or marketed to produce effects similar to THC. FDA was also directed to clarify what counts as a product “container.”
None of that information had been published as of August 2026, according to an updated Congressional Research Service analysis.
The law’s 0.4-milligram-per-container limit depends heavily on which cannabinoids are counted and how “container” is interpreted. Yet businesses are being expected to prepare for compliance without those answers.
Full-Spectrum Hemp Is in the Crosshairs
Unless Congress intervenes, the new federal definition of hemp is scheduled to take effect November 12, 2026. Many non-intoxicating, full-spectrum CBD oils naturally contain trace quantities of THC, which means these products could disappear under the new policy. We explained this further in previous coverage. Put briefly, the risk assessment underpinning these restrictions is deeply flawed and unscientific. It would be like banning coffee because caffeine at high doses can be harmful.
ANH-USA supports targeted restrictions on dangerous synthetic intoxicants, adulterated products, deceptive marketing, and sales to minors. But Congress should not use those legitimate concerns to eliminate responsibly made, non-intoxicating hemp products that adults choose for their personal wellness.
A One-Month Bridge Is Not Enough
Congress has recently approved a funding measure that would delay most of the hemp restrictions until December 11 while allowing the ban on synthetic derivatives to proceed. The last step is for President Trump to sign the bill into law, which he is expected to do. This is positive but still a stopgap measure.
The bipartisan Hemp Planting Predictability Act, S. 3686 and H.R. 7024, offers a more meaningful pause. It would extend the implementation period from one year to three years, giving Congress time to build a workable regulatory framework instead of forcing an industry-wide crisis.
Regulation Without Erasing Access
The stronger long-term path is the Cannabinoid Safety and Regulation Act, S. 3474, introduced by Senators Ron Wyden and Jeff Merkley.
The bill would establish manufacturing, testing, labeling, registration, and age requirements for cannabinoid products. It would create a federal pathway for cannabinoid dietary supplements and permit truthful, substantiated structure-function statements. It also provides mechanisms for removing dangerous synthetic and semi-synthetic cannabinoids from the market.
That is the distinction Congress must preserve: regulate products according to their actual risks, rather than treating trace amounts in natural hemp extracts like high-dose intoxicants.
FDA’s missed deadline shows why consumers cannot rely on agency promises alone. Congress must protect access explicitly in law.
Tell your members of Congress to support the Cannabinoid Safety and Regulation Act and the Hemp Planting Predictability Act. Consumers deserve safe, tested, clearly labeled products without losing access to the full spectrum of hemp’s natural compounds.
Action Alert!
